Shire to Present Data on Using the MaxCyte Transient Gene Expression Platform in Development Programs
Gaithersburg, MD, March 9, 2016 – MaxCyte® Inc., the leader in driving the next generation of cell-based medicines with scalable, high-performance cell transfection systems, announces that new data on the development of a transient gene expression platform for CHO GS knockout cells using MaxCyte’s flow electroporation technology will be presented at IBC’s Inaugural Bioprocess International West Conference in Oakland, CA, on March 16, 2016.
Speaker: Brian Pescatore, MS
Protein/Antibody Engineering, Discovery Therapeutics, Shire
Title: Development of a Transient Gene Expression Platform for CHO GS Knockout Cells Using Flow Electroporation Technology
Date: Wednesday, March 16, 2016
Time: 12:05-12:35 pm
Location: Oakland Marriott City Center, Oakland, CA
In addition, MaxCyte scientists will be available for technical discussions in booth 514.
About MaxCyte
MaxCyte is the leader in driving the next generation of cell-based medicines. Flow electroporation, MaxCyte’s cell modification technology, is used for discovery, development, and manufacture of small molecule, biologic, and cell-based therapeutics. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of transfected cells for a broad array of applications.
